Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Post time 2024-6-7 11:06:31

Edited by drvuhoang123 at 2024-6-7 11:31

[size=0.7]Articles
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial[size=0.8]Author links open overlay panelProf Silvio Danese MD a[size=0.8], Prof Remo Panaccione MD b[size=0.8], Prof Brian G Feagan MD c[size=0.8], Prof Anita Afzali MD d[size=0.8], Prof David T Rubin MD e[size=0.8], Prof Bruce E Sands MD f[size=0.8], Walter Reinisch MD g[size=0.8], Julián Panés MD h[size=0.8], Aparna Sahoo DO i[size=0.8], Natalie A Terry MD i[size=0.8], Daphne Chan PhD j[size=0.8], Chenglong Han MD i[size=0.8], Mary Ellen Frustaci MAS i[size=0.8], Zijiang Yang PhD i[size=0.8], Prof William J Sandborn MD k l[size=0.8], Prof Tadakazu Hisamatsu MD m[size=0.8], Prof Jane M Andrews MD n[size=0.8], Prof Geert R D'Haens MD o[size=0.8]GALAXI-1 Study Group
[size=0.8]

Article link：

https://www.sciencedirect.com/science/article/abs/pii/S2468125323003187

[size=0.8]

[size=0.8]

[size=0.8]

[size=0.8]

[size=0.8]

Post time 2024-6-7 11:06:32

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today